110 related articles for article (PubMed ID: 35245746)
21. Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.
Sugano T; Yoshida M; Masuda M; Ono M; Tamura K; Kinoshita T; Tsuda H; Honda K; Gemma A; Yamada T
Br J Cancer; 2020 Jun; 122(12):1811-1817. PubMed ID: 32265507
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
[TBL] [Abstract][Full Text] [Related]
23. Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
Elsamany S; Elmorsy S; Alzahrani A; Rasmy A; Abozeed WN; Mohammed AA; Sherisher MA; Abbas MM; Mashhour M
Asian Pac J Cancer Prev; 2015; 16(17):7975-9. PubMed ID: 26625828
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
25. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A;
Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years.
Fernandez G; Prastawa M; Madduri AS; Scott R; Marami B; Shpalensky N; Cascetta K; Sawyer M; Chan M; Koll G; Shtabsky A; Feliz A; Hansen T; Veremis B; Cordon-Cardo C; Zeineh J; Donovan MJ
Breast Cancer Res; 2022 Dec; 24(1):93. PubMed ID: 36539895
[TBL] [Abstract][Full Text] [Related]
27. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Cuzick J; Dowsett M; Pineda S; Wale C; Salter J; Quinn E; Zabaglo L; Mallon E; Green AR; Ellis IO; Howell A; Buzdar AU; Forbes JF
J Clin Oncol; 2011 Nov; 29(32):4273-8. PubMed ID: 21990413
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of a Next-Generation Sequencing-Based Multigene Assay to Predict the Prognosis of Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Lee HB; Lee SB; Kim M; Kwon S; Jo J; Kim J; Lee HJ; Ryu HS; Lee JW; Kim C; Jeong J; Kim H; Noh DY; Park IA; Ahn SH; Kim S; Yoon S; Kim A; Han W
Clin Cancer Res; 2020 Dec; 26(24):6513-6522. PubMed ID: 33028590
[TBL] [Abstract][Full Text] [Related]
30. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
31. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
33. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
Chen X; Fan Y; Xu B
Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
[TBL] [Abstract][Full Text] [Related]
34. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
[TBL] [Abstract][Full Text] [Related]
35. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
Buechler SA; Gökmen-Polar Y; Badve SS
Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
37. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
38. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
[TBL] [Abstract][Full Text] [Related]
39. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]